{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:27:06Z","timestamp":1791052026776,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Staging hepatic fibrosis by liver biopsy guides prognosis and treatment of hepatitis C, but is invasive and expensive. We sought to create an algorithm of serum markers that accurately and reliably predict liver fibrosis stage among hepatitis C patients.<\/jats:p>\n                  <jats:p>Methods: Ten biochemical markers were measured at time of liver biopsy in 117 untreated hepatitis C patients (training set). Multivariate logistic regression and ROC curve analyses were used to create a predictive model for significant fibrosis (METAVIR F2, F3, and F4), advanced fibrosis (F3 and F4), and cirrhosis (F4). The model was validated in 104 patients from other institutions.<\/jats:p>\n                  <jats:p>Results: A model (Hepascore) of bilirubin, \u03b3-glutamyltransferase, hyaluronic acid, \u03b12-macroglobulin, age, and sex produced areas under the ROC curves (AUCs) of 0.85, 0.96, and 0.94 for significant fibrosis, advanced fibrosis, and cirrhosis, respectively. In the training set, a score \u22650.5 (range, 0.0\u20131.0) was 92% specific and 67% sensitive for significant fibrosis, a score &amp;lt;0.5 was 81% specific and 95% sensitive for advanced fibrosis, and a score &amp;lt;0.84 was 84% specific and 71% sensitive for cirrhosis. Among the validation set, the AUC for significant fibrosis, advanced fibrosis, and cirrhosis were 0.82, 0.90, and 0.89, respectively. A score \u22650.5 provided a specificity and sensitivity of 89% and 63% for significant fibrosis, whereas scores &amp;lt;0.5 had 74% specificity and 88% sensitivity for advanced fibrosis.<\/jats:p>\n                  <jats:p>Conclusions: A model of 4 serum markers plus age and sex provides clinically useful information regarding different fibrosis stages among hepatitis C patients.<\/jats:p>","DOI":"10.1373\/clinchem.2005.048389","type":"journal-article","created":{"date-parts":[[2005,7,29]],"date-time":"2005-07-29T20:12:39Z","timestamp":1122667959000},"page":"1867-1873","source":"Crossref","is-referenced-by-count":439,"title":["Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection"],"prefix":"10.1093","volume":"51","author":[{"given":"Leon A","family":"Adams","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bulsara","sequence":"first","affiliation":[{"name":"School of Population Health and School of Medicine and Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Rossi","sequence":"first","affiliation":[{"name":"PathCentre, Queen Elizabeth II Medical Centre, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"DeBoer","sequence":"first","affiliation":[{"name":"PathCentre, Queen Elizabeth II Medical Centre, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Speers","sequence":"first","affiliation":[{"name":"PathCentre, Queen Elizabeth II Medical Centre, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"first","affiliation":[{"name":"Storr Liver Unit, Westmead Millennium Institute, Westmead Hospital, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kench","sequence":"first","affiliation":[{"name":"Storr Liver Unit, Westmead Millennium Institute, Westmead Hospital, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Farrell","sequence":"first","affiliation":[{"name":"Storr Liver Unit, Westmead Millennium Institute, Westmead Hospital, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey W","family":"McCaughan","sequence":"first","affiliation":[{"name":"AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P","family":"Jeffrey","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, Australia"},{"name":"The University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,10,1]]},"reference":[{"key":"2020022801001256900_R1","doi-asserted-by":"crossref","unstructured":"Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat1999;6:35-47.","DOI":"10.1046\/j.1365-2893.1999.6120139.x"},{"key":"2020022801001256900_R2","doi-asserted-by":"crossref","unstructured":"Kim WR. The burden of hepatitis C in the United States. Hepatology2002;36:S30-S34.","DOI":"10.1053\/jhep.2002.36791"},{"key":"2020022801001256900_R3","doi-asserted-by":"crossref","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet1997;349:825-832.","DOI":"10.1016\/S0140-6736(96)07642-8"},{"key":"2020022801001256900_R4","doi-asserted-by":"crossref","unstructured":"Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology2002;36:S47-S56.","DOI":"10.1002\/hep.1840360707"},{"key":"2020022801001256900_R5","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002;347:975-982.","DOI":"10.1056\/NEJMoa020047"},{"key":"2020022801001256900_R6","doi-asserted-by":"crossref","unstructured":"Booth JC, O\u2019Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut2001;49:I1-I21.","DOI":"10.1136\/gut.49.suppl_1.I1"},{"key":"2020022801001256900_R7","doi-asserted-by":"crossref","unstructured":"EASL International Consensus Conference on Hepatitis C. Paris, 26\u201327 February 1999. Consensus statement. J Hepatol1999;31:3-8.","DOI":"10.1016\/S0168-8278(99)80367-5"},{"key":"2020022801001256900_R8","doi-asserted-by":"crossref","unstructured":"Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology2004;39:1147-1171.","DOI":"10.1002\/hep.20119"},{"key":"2020022801001256900_R9","doi-asserted-by":"crossref","unstructured":"Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut1995;36:437-441.","DOI":"10.1136\/gut.36.3.437"},{"key":"2020022801001256900_R10","doi-asserted-by":"crossref","unstructured":"Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med2001;344:495-500.","DOI":"10.1056\/NEJM200102153440706"},{"key":"2020022801001256900_R11","doi-asserted-by":"crossref","unstructured":"Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol2002;97:2614-2618.","DOI":"10.1111\/j.1572-0241.2002.06038.x"},{"key":"2020022801001256900_R12","doi-asserted-by":"crossref","unstructured":"Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med2003;163:218-224.","DOI":"10.1001\/archinte.163.2.218"},{"key":"2020022801001256900_R13","doi-asserted-by":"crossref","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology2003;38:518-526.","DOI":"10.1053\/jhep.2003.50346"},{"key":"2020022801001256900_R14","doi-asserted-by":"crossref","unstructured":"Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology2004;39:1456-1457.","DOI":"10.1002\/hep.20226"},{"key":"2020022801001256900_R15","doi-asserted-by":"crossref","unstructured":"Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology2002;36:986-992.","DOI":"10.1053\/jhep.2002.36128"},{"key":"2020022801001256900_R16","doi-asserted-by":"crossref","unstructured":"Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology2004;39:1239-1247.","DOI":"10.1002\/hep.20207"},{"key":"2020022801001256900_R17","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol2000;15:945-951.","DOI":"10.1046\/j.1440-1746.2000.02233.x"},{"key":"2020022801001256900_R18","doi-asserted-by":"crossref","unstructured":"Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol1997;26:574-583.","DOI":"10.1016\/S0168-8278(97)80423-0"},{"key":"2020022801001256900_R19","doi-asserted-by":"crossref","unstructured":"Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet2001;357:1069-1075.","DOI":"10.1016\/S0140-6736(00)04258-6"},{"key":"2020022801001256900_R20","doi-asserted-by":"crossref","unstructured":"Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem2003;49:450-454.","DOI":"10.1373\/49.3.450"},{"key":"2020022801001256900_R21","doi-asserted-by":"crossref","unstructured":"Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of \u03b12-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Lond)1998;95:179-186.","DOI":"10.1042\/cs0950179"},{"key":"2020022801001256900_R22","doi-asserted-by":"crossref","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology1996;24:289-293.","DOI":"10.1002\/hep.510240201"},{"key":"2020022801001256900_R23","doi-asserted-by":"crossref","unstructured":"Azer SA, Murray M, Farrell GC, Stacey NH. Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. Hepatology1993;18:1224-1231.","DOI":"10.1002\/hep.1840180531"},{"key":"2020022801001256900_R24","doi-asserted-by":"crossref","unstructured":"Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol2003;39:222-230.","DOI":"10.1016\/S0168-8278(03)00171-5"},{"key":"2020022801001256900_R25","doi-asserted-by":"crossref","unstructured":"Vrochides D, Papanikolaou V, Pertoft H, Antoniades AA, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. Hepatology1996;23:1650-1655.","DOI":"10.1002\/hep.510230648"},{"key":"2020022801001256900_R26","doi-asserted-by":"crossref","unstructured":"Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol2004;41:935-942.","DOI":"10.1016\/j.jhep.2004.08.008"},{"key":"2020022801001256900_R27","doi-asserted-by":"crossref","unstructured":"Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology2004;127:1704-1713.","DOI":"10.1053\/j.gastro.2004.08.052"},{"key":"2020022801001256900_R28","doi-asserted-by":"crossref","unstructured":"Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology2003;38:481-492.","DOI":"10.1053\/jhep.2003.50319"},{"key":"2020022801001256900_R29","doi-asserted-by":"crossref","unstructured":"Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat2002;9:128-133.","DOI":"10.1046\/j.1365-2893.2002.00341.x"},{"key":"2020022801001256900_R30","doi-asserted-by":"crossref","unstructured":"Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology2004;39:862-863author reply 863.","DOI":"10.1002\/hep.20099"},{"key":"2020022801001256900_R31","doi-asserted-by":"crossref","unstructured":"Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology2005;128:343-350.","DOI":"10.1053\/j.gastro.2004.11.018"},{"key":"2020022801001256900_R32","doi-asserted-by":"crossref","unstructured":"Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology2005;41:257-264.","DOI":"10.1002\/hep.20535"},{"key":"2020022801001256900_R33","doi-asserted-by":"crossref","unstructured":"O\u2019Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol2000;114:712-718.","DOI":"10.1309\/D7AU-EYW7-4B6C-K08Y"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/10\/1867\/32684765\/clinchem1867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/10\/1867\/32684765\/clinchem1867.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T18:00:45Z","timestamp":1683136845000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/51\/10\/1867\/5629502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,10,1]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2005.048389","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,10,1]]},"published":{"date-parts":[[2005,10,1]]}}}